Valuation: Immatics N.V.

Market Cap 1.14B 1B 944M 861M 1.61B 109B 1.62B 11.33B 4.39B 55.63B 4.28B 4.18B 181B P/E 2026 *
-3.94x
P/E 2027 * -3.96x
Enterprise Value 852M 750M 707M 645M 1.21B 81.83B 1.22B 8.48B 3.29B 41.65B 3.2B 3.13B 136B EV / Sales 2026 *
18.3x
EV / Sales 2027 * 20.2x
Free-Float
76.83%
Yield 2026 *
-
Yield 2027 * -
1 week-5.44%
Current month-12.49%
1 month-3.92%
3 months-16.85%
6 months-9.15%
Current year-20.50%
1 week 8.06
Extreme 8.06
8.88
1 month 8.06
Extreme 8.06
9.87
3 years 3.34
Extreme 3.34
13.75
5 years 3.34
Extreme 3.34
14.89
Manager TitleAgeSince
Chief Executive Officer 51 01/01/2019
Director of Finance/CFO 57 01/10/2025
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 51 01/07/2020
Chairman 70 01/10/2012
Director/Board Member 72 01/07/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%-5.44%+13.78%-28.72% 1.14B
-3.30%+1.19%+54.62%+104.15% 71.94B
+1.25%-3.01%+40.12%+77.12% 59.35B
+2.12%+5.79%+32.63%+24.27% 27.16B
-3.65%-3.04%-14.19%+351.34% 26.54B
-0.36%+2.72%+0.61%-4.31% 24.93B
+0.40%+0.75%+22.91%-9.68% 20.61B
-1.70%-3.35%+146.86%+325.69% 15.03B
+0.21%+1.21%-6.26%+493.02% 14.2B
-0.09%-1.01%+49.32%+164.64% 14.36B
Average -0.55%-0.12%+34.04%+149.75% 30.46B
Weighted average by Cap. -0.81%-0.24%+36.87%+130.70%

Financials

2026 *2027 *
Net sales 46.54M 40.94M 38.59M 35.21M 65.84M 4.47B 66.35M 463M 179M 2.27B 175M 171M 7.4B 39.58M 34.82M 32.82M 29.94M 56M 3.8B 56.44M 394M 153M 1.93B 149M 145M 6.29B
Net income -287M -253M -238M -217M -407M -27.59B -410M -2.86B -1.11B -14.04B -1.08B -1.06B -45.69B -310M -272M -257M -234M -438M -29.72B -441M -3.08B -1.19B -15.13B -1.16B -1.14B -49.23B
Net Debt -286M -252M -237M -217M -405M -27.47B -408M -2.85B -1.1B -13.98B -1.07B -1.05B -45.5B -339M -298M -281M -256M -479M -32.51B -483M -3.37B -1.31B -16.55B -1.27B -1.24B -53.85B
Logo Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
Employees
-
Date Price Change
26/09/26 USD 8.430 +1.08%
24/09/26 USD 8.340 -3.02%
23/09/26 USD 8.600 -2.99%
22/09/26 USD 8.865 +1.66%
21/09/26 USD 8.720 +1.40%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
8.330USD
Average target price
17.63USD
Spread / Average Target
+111.68%

Quarterly revenue - Rate of surprise